UltraTouch starts Palpagraph breast mapping trials:
This article was originally published in Clinica
Executive Summary
UltraTouch is starting clinical trials for a breast mapping technology, which it claims can map tumours 16 times smaller than those detected by hand - which are smaller than those routinely detected by mammography in premenopausal women. The Palpagraph scans the breast by computer-controlled mechanical palpation (light touch). It uses no radiation and is painless. The information is collected and stored in medical records as a standardised BreastMap. UltraTouch of Exton, Philadelphia, plans to use the clinical trial data to support applications to market the device in the US and Europe.
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.